Opiate Addiction Clinical Trials 2022

Browse 236 Opiate Addiction Medical Studies Across 173 Cities

21 Phase 3 Trial · 450 Opiate Addiction Clinics

Reviewed by Michael Gill, B. Sc.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Educational Materialsfor Opioids Use

Iowa City, IA
18+
All Sexes
Opioid medications are widely used after many orthopedic procedures and are routinely prescribed after shoulder replacement surgery. Despite the high prevalence of opioid abuse and misuse, there is no standardized mechanism for patients to dispose of unused opioid medications safely and securely and the average number of opioid pills required after shoulder replacement surgery is still unknown. In a prior pilot study conducted by our group (IRB# 202012142), opioid consumption patterns of patients undergoing shoulder arthroplasty were analyzed, as well as their adherence to a safe and secure disposal mechanism for excess opioid pills. A 94% retention rate was achieved and preliminary results showed that most of the subjects were 60 years of age and older. The objective of the current proposal is to: (1) develop pre-operative education materials related to post-operative opioid use following shoulder arthroplasty; (2) pilot the impact of this educational intervention; (3) examine the effect of providing disposal mechanisms for unused opioid pain medications following shoulder arthroplasty. The proposal is to conduct a single blinded randomized controlled trial of patients undergoing total shoulder replacement, both anatomic total shoulder arthroplasty (TSA) and reverse shoulder arthroplasty (RSA), and Hemiarthroplasty at UIHC. This randomized controlled trial will compare: (1) education plus opioid disposal to the standard of care (SC). The investigators hypothesize that pre-operative opioid education modules combined with a structured opioid disposal program will decrease opioid consumption following shoulder arthroplasty.
Waitlist Available
Has No Placebo
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Families Actively Improving Relationships (FAIR)for Opioid Abuse

Eugene, OR
< 65
All Sexes
Young parents aged 16 to 30, involved in the DHS system for child welfare or self-sufficiency needs are at risk for opioid use disorder and/or methamphetamine use disorder (OUD; MUD). Those identified as engaging in opioid or methamphetamine misuse are at high risk for escalation. Children of parents with OUD and MUD are at-risk for entering into foster care. Oregon is one state particularly affected by this challenge. The proposed UG3/UH3 offers one potential solution by adapting and evaluating a recently developed treatment for parental OUD and MUD, for prevention. This study seeks to collaborate with Oregon Department of Humans Services (DHS) leadership to deliver a new outpatient prevention program to high-risk, young, parents. The Families Actively Improving Relationships (FAIR) program will include community-based mental health, parent management, and ancillary needs treatment, and ongoing monitoring and prevention services for opioid and methamphetamine use. This study will randomize 240 parents, aged 16 to 30, to receive FAIR or standard case management and referral, in two counties in Oregon. Outcomes will include an evaluation of the effectiveness of FAIR in addressing risk factors associated with substance use disorders in DHS-involved populations, OUD and MUD outcomes, and implementation outcomes including implementation process and milestones, and program delivery outcomes. Intervention and Implementation costs will be assessed, and the benefit of FAIR will be evaluated in relation to standard services, but also in relation to capacity and population needs. Study hypotheses are: (1) Parents randomized to FAIR will be less likely to escalate opioid and/or methamphetamine use, and to receive a diagnosis of OUD and/or MUD; (2) Parents randomized to FAIR will experience significant reductions in mental health, parent skills, and ancillary needs compared to those receiving standard services; (3) Counties will follow the implementation plan developed in collaboration between study team members and state leadership, and that doing so will yield successful implementation of FAIR; and (4) Implementation and intervention costs for FAIR will demonstrate a benefit for offering FAIR compared to standard services, particularly in rural communities where capacity influences service delivery decisions.
Recruiting
Has No Placebo
25 Opiate Addiction Clinical Trials Near Me
Iowa City, IA
Birmingham, AL
Eugene, OR
Little Rock, AR
More Trial Locations
An interactive map to display trial locations for University of Iowa, University of Alabama at Birmingham, OSLC, Brain Imaging Research Center, and 31 more locations.
Most Popular References for Opiate Addiction Clinical Trials
Frequency
Citation
Top Hospitals for Opiate Addiction Clinical Trials
Location
Active Opiate Addiction Clinical Trials
All Time Trials for Opiate Addiction
First Recorded Opiate Addiction Trial
Trials
Medical University of South Carolina, Charleston, South Carolina
7
9
2017
Vanderbilt University Medical Center, Nashville, Tennessee
6
8
2016
Top Treatments for Opiate Addiction Clinical Trials
Treatment Name
Active Opiate Addiction Clinical Trials
All Time Trials for Opiate Addiction
First Recorded Opiate Addiction Trial
Trials
Top Cities for Opiate Addiction Clinical Trials
City
Active Opiate Addiction Clinical Trials
Top Active Site for Opiate Addiction Clinical Trials
Trial List
Pittsburgh, Pennsylvania
15
Pregnancy Recovery Center at Magee-Womens Hospital of UPMC
Most Recent Opiate Addiction Clinical Trials
Phase 3 Opiate Addiction Clinical Trials
Pediatric Opiate Addiction Clinical Trials
Senior Friendly Opiate Addiction Clinical Trials
Recently Completed Studies with FDA Approved Treatments for Opiate Addiction
Treatment
Year
Mechanism of Action
Sponsor
Active Opiate Addiction Clinical Trials
ALA-1000
2019
Buprenorphine
Alar Pharmaceuticals Inc.
13
Sofosbuvir/Velpatasvir
2018
Sofosbuvir + Velpatasvir
Elizabeth Krans, MD
2

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 17th, 2021

Last Reviewed: August 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.